Maribavir

Product Name:    BENZIMIDAVIR

Synonyms:    Maribavi;5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(BETA-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE;BENZIMIDAVIR;BENZIMIDAVIR, 5,6-DICHLORO-2-（ISOPROPYLAMINO）-1-(β-L-RIBOFURANOSYL)-LH-BENZIMIDAZOLE;5,6-DICHLORO-2-ISOPROPYLAMINO-1-(-L-RIBOFURANOSYL)-LH-BENZIMIDAZOLE;BENZIMIDAVIR: 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(SS-L-RIBOFURANOSYL)-LH-BENZIMIDAZOLE;(2S,3S,4R,5S)-2-(5,6-Dichloro-2-(isopropylamino)-1H-benzo[d]-imidazol-1-yl)-5-(hydroxymethyl)tetr;Maribavir

CAS:    176161-24-3

MF:    C15H19Cl2N3O4

MW:    376.24

Product Categories:    Inhibitors

Maribavir is an orally bioavailable benzimidazole L-riboside antiviral, with a spectrum of activity essentially limited to human cytomegalovirus (CMV) and Epstein–Barr virus (EBV). It is an inhibitor of the CMV UL97 kinase. As of 2008, maribavir was in phase III clinical trials for prevention of CMV infection in transplant recipients at risk. Earlier phase I and II trials of maribavir showed anti-CMV activity with an acceptable adverse effect profile. Investigational drug code names include 1263W94, BW1263-W94, GW257406X, and VP41263, reflecting changes in ownership during drug development. As of early 2009, the drug was being developed under ‘‘fast track’’ status granted by the US Food and Drug Administration, but the apparent failure of maribar prophylaxis to prevent CMV infection in stem cell transplant recipients in the definitive phase III clinical trial resulted in the sponsor halting ongoing clinical development.